by nms-sync | Sep 2, 2024 | News
NERVIANO, IT, September 2, 2024 SIMIS S.r.l. (SIMIS), a part of NMS Group S.p.A. (NMS Group) and a company provides services to the community domiciled in Nerviano Bio-Park, today announced the appointment of Marco Dieci as the new Chief Executive Officer, effective...
by xiaohong.wu@demo112.axxiem.com | Aug 23, 2024 | 2024, News
We are honored to have two senior scientists speaking at the SCI-2024 – XXVIII National Congress in Milan. Elena Ardini: Wednesday, August 28th 8:30am – 9:00am Discovery of entrectinib: an amazing journey from target biology to innovative therapy (KN-028)...
by NMSGroup | Aug 22, 2024 | 2024, News
Thrilled to announce that our latest paper, in collaboration with Prof. Gian Cesare Tron from Università del Piemonte Orientale (UPO), has just been published in the prestigious “Chemistry – A European Journal”! You can check it out here: link. This publication...
by nms-sync | Jun 24, 2024 | News
NMS-812: A clinical phase potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the integrated stress response (ISR)
The United States Food and Drug Administration (FDA) has cleared the protocol for new investigational new drug...
by xiaohong.wu@demo112.axxiem.com | Jun 21, 2024 | 2024, News
NERVIANO, IT and BOSTON, Mass, June 21 , 2024 – Nerviano Medical Sciences S.r.l. (“NMS” or the “Company”), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and...
by NMSGroup | May 28, 2024 | 2024, News
NERVIANO, 28, May 2024_Nerviano Medical Sciences S.r.l. (NMS), a wholly owned subsidiary of NMS Group S.p.A, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced, following the shareholder...
Welcome and Check out our new motion picture!
Recent Comments